The regulatory effect of miR-5195-3p on LOX mRNA expression and its expression pattern in patients with pelvic organ prolapse. Note: (A) Bioinformatics analysis predicted a binding site between miR-5195-3p and the 3′ untranslated region of LOX mRNA, as shown in the schematic diagram. (B) The interaction between miR-5195-3p and LOX mRNA was functionally validated using the dual luciferase reporter gene assay. Compared to the miR-NC (negative control) group, the experimental group showed significant differences at P < 0.05, indicating a significant binding. (C) Real-time reverse transcription PCR (qRT-PCR) analysis revealed differential expression of LOX mRNA in vaginal wall tissues of patients without pelvic organ prolapse (non-POP) and pelvic POP patients. (D) Western blot analysis showed differential expression of LOX protein in vaginal wall tissues of non-POP patients and POP patients. Significant differences were observed compared to the normal group at P < 0.05 and to the POP I-II stage group at ^#P < 0.05. (E) Pearson correlation analysis demonstrated a negative correlation between miR-5195-3p and LOX mRNA expression levels in vaginal wall tissues of POP patients. (F) The expression level of miR-5195-3p in fibroblasts was analyzed using qRT-PCR. (G) QRT-PCR analysis assessed the impact on LOX mRNA expression in fibroblasts after transfection with a miR-5195-3p inhibitor. All cell experiments were repeated three times. (H) Western blot analysis evaluated the transfection effect of the miR-5195-3p inhibitor on LOX protein expression levels in fibroblasts. ^* represents a comparison with the control group at P < 0.05; ^# represents a comparison with the POP + inhibitor NC group at P < 0.05.